抗TNF联合低剂量甲氨蝶呤与抗TNF单药治疗儿童克罗恩病的比较效果:一项实用性随机试验
该多中心、随机、双盲、安慰剂对照实用性试验纳入297例起始英夫利西单抗或阿达木单抗的儿童克罗恩病患者,1:1分配至口服甲氨蝶呤或安慰剂,随访12-36个月。总体人群治疗失败时间无差异(HR 0.69,95%CI 0.45-1.05);阿达木单抗起始者联合治疗组治疗失败时间更长(HR 0.40,95%CI 0.19-0.81),英夫利西单抗起始者无差异(HR 0.93,95%CI 0.55-1.56)。
要点
- 总体人群联合治疗与单药治疗的治疗失败时间无显著差异(HR 0.69,95%CI 0.45-1.05)。
- 阿达木单抗起始者联合治疗组治疗失败风险低于单药组(HR 0.40,95%CI 0.19-0.81)。
- 英夫利西单抗起始者联合与单药治疗无差异(HR 0.93,95%CI 0.55-1.56)。
核心结论
- 在阿达木单抗起始者中,甲氨蝶呤联合治疗组治疗失败较单药组减少约2倍,安全性可耐受;英夫利西单抗起始者中未观察到该差异。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照实用性试验,纳入297例起始英夫利西单抗或阿达木单抗的儿童克罗恩病患者,1:1分配至甲氨蝶呤或安慰剂,随访12-36个月。
- 156例分配至甲氨蝶呤组(英夫利西单抗起始110例,阿达木单抗起始46例),141例分配至安慰剂组(英夫利西单抗起始102例,阿达木单抗起始39例);平均年龄13.9岁,女性占35%。
主要发现
- 总体人群中,治疗失败时间在两组间无差异(HR 0.69,95%CI 0.45-1.05)。
- 英夫利西单抗起始者中,联合治疗与单药治疗无差异(HR 0.93,95%CI 0.55-1.56)。
- 阿达木单抗起始者中,联合治疗与更长的治疗失败时间相关(HR 0.40,95%CI 0.19-0.81)。
- 抗药抗体产生在联合治疗组呈降低趋势但未达显著(英夫利西单抗:OR 0.72,95%CI 0.49-1.07;阿达木单抗:OR 0.71,95%CI 0.24-2.07)。
- 患者报告结局(疼痛干扰和疲劳)未见差异;联合治疗组不良事件更多但严重不良事件更少。
关键数值与推荐
- 主要结局为治疗失败的复合指标。
- 次要结局包括抗药抗体和患者报告结局(疼痛干扰和疲劳)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Tumor necrosis factor inhibitors, including infliximab and adalimumab, are a mainstay of pediatric Crohn's disease therapy; however, nonresponse and loss of response are common. As combination therapy with methotrexate may improve response, we performed a multicenter, randomized, double-blind, placebo-controlled pragmatic trial to compare tumor necrosis factor inhibitors with oral methotrexate to tumor necrosis factor inhibitor monotherapy. METHODS: Patients with pediatric Crohn's disease initiating infliximab or adalimumab were randomized in 1:1 allocation to methotrexate or placebo and followed for 12-36 months. The primary outcome was a composite indicator of treatment failure. Secondary outcomes included anti-drug antibodies and patient-reported outcomes of pain interference and fatigue. Adverse events (AEs) and serious AEs (SAEs) were collected. RESULTS: Of 297 participants (mean age, 13.9 years, 35% were female), 156 were assigned to methotrexate (110 infliximab initiators and 46 adalimumab initiators) and 141 to placebo (102 infliximab initiators and 39 adalimumab initiators). In the overall population, time to treatment failure did not differ by study arm (hazard ratio, 0.69; 95% CI, 0.45-1.05). Among infliximab initiators, there were no differences between combination and monotherapy (hazard ratio, 0.93; 95% CI, 0.55-1.56). Among adalimumab initiators, combination therapy was associated with longer time to treatment failure (hazard ratio, 0.40; 95% CI, 0.19-0.81). A trend toward lower anti-drug antibody development in the combination therapy arm was not significant (infliximab: odds ratio, 0.72; 95% CI, 0.49-1.07; adalimumab: odds ratio, 0.71; 95% CI, 0.24-2.07). No differences in patient-reported outcomes were observed. Combination therapy resulted in more AEs but fewer SAEs. CONCLUSIONS: Among adalimumab but not infliximab initiators, patients with pediatric Crohn's disease treated with methotrexate combination therapy experienced a 2-fold reduction in treatment failure with a tolerable safety profile. CLINICALTRIALS: gov, Number: NCT02772965.
引用
- Kappelman MD, Wohl DA, Herfarth HH, et al. Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized Trial. Gastroenterology. 2023. PMID: 37004887. doi:10.1053/j.gastro.2023.03.224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。